April Breyer Menon, Author at Venable's BiologicsHQ

Will Product Drift Cause a Rift?

by April Breyer Menon | Jul 1, 2019

Venable partner Ha Kung Wong discusses the impact of product drift on biosimilars in an article for Pharm Manufacturing, including the opportunity for product drift concerns to be addressed by the FDA as part of its Biosimilar Action Plan. The article can be viewed...

How Can Biosimilars Make Headway in the U.S. Market?

by April Breyer Menon | Jun 26, 2019

Venable partner Ha Kung Wong spoke at ISPOR’s annual conference as part of a panel that discussed the biosimilar market in the US. As a follow-up to that presentation, Ha Kung participated in a Q&A for Biosimilar Development, including providing thoughts...

Comparing the Economics of Biosimilars and Generics

by April Breyer Menon | Jun 25, 2019

Venable partner Ha Kung Wong spoke at the ACI 10th Summit on Biosimilars as part of a panel that reviewed the economics of biosimilars and generic drugs. Highlights from his presentation comparing biosimilar markets in Europe and the United States and his take-home...

New Bill Would Reshape Drug Patent Cases in Uncertain Ways

by April Breyer Menon | Jun 14, 2019

Venable partner Ha Kung Wong commented on the Terminating the Extension of Rights Misappropriated Act, or TERM Act, H.R. 3199, as part of the Law360 article “New Bill Would Reshape Drug Patent Cases in Uncertain Ways,” available here. The TERM Act was...

Venable’s BiologicsHQ Monthly Injection – May 2019

by April Breyer Menon | Jun 6, 2019

Download PDF Download...

« Older Entries

Next Entries »

Methodology

Information contained in the Venable BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable BiologicsHQ database.

Disclaimer

The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.